Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 462 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Height Clear all
Completed Phase 1Phase 2 Interventional Results available

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT01559363
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 62 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 6, 2026, 7:33 AM EDT
Recruiting Not applicable Interventional

Postpartum Exercise Intervention

NCT07613333
View directory record Official record
Conditions
Postpartum, Neuromuscular Adaptations, Abdominal Muscles, Pelvic Floor Dysfunctions, Physical Activity
Interventions
Progressive exercise, Active Straight Leg Raise Test, Active Straight Leg Raise Fatigue Task, Lower Extremity Strength Testing, Ultrasound imaging of abdominal wall, Pelvic Floor Muscle Strength Testing, Pelvic Floor Muscle Endurance Testing
Other · Diagnostic Test
Lead sponsor
Carroll University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 6, 2026, 7:33 AM EDT
Recruiting Phase 2 Interventional

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 6, 2026, 7:33 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Stand Up Kansas: An Intervention to Reduce Sedentary Behavior in the Home Work Environment

NCT04641689
View directory record Official record
Conditions
Sedentary Behavior, Behavior, Health, Cholesterolemia, Obesity, Stress, Hypertension, Fatigue, Glucose, High Blood, Mood
Interventions
Desk Only, Program Only
Device · Behavioral
Lead sponsor
Kansas State University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 6, 2026, 7:33 AM EDT
Withdrawn Phase 4 Interventional

Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine

NCT06784180
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Morphine, Bupivacaine, Fentanyl, Hydromorphone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 6, 2026, 7:33 AM EDT
Recruiting No phase listed Observational

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

NCT07702461
View directory record Official record
Conditions
Obesity & Overweight, Diabetes (DM)
Interventions
Glucagon-Like Peptide-1 Agonist (GLP-1)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 6, 2026, 7:33 AM EDT
Terminated Phase 3 Interventional

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187
View directory record Official record
Conditions
Corneal Diseases, Cornea Transplant
Interventions
LX201, Placebo
Drug · Other
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Not applicable Interventional Results available

Alternative EndoCrowns Designs for Chairside CAD/CAM

NCT04604314
View directory record Official record
Conditions
Endodontically Treated Teeth
Interventions
CEREC Tessera
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 110 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Phase 2 Interventional

Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome

NCT00001221
View directory record Official record
Conditions
Gonadal Dysgenesis, Turner's Syndrome
Interventions
Growth Hormone (Humatrope)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Not applicable Interventional

MyLife: A Digital Health Coaching Program

NCT03529903
View directory record Official record
Conditions
Lifestyle-related Condition, Obesity, Sedentary Lifestyle, PreDiabetes, Hypertension
Interventions
Health Coaching
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 6, 2026, 7:33 AM EDT
Completed No phase listed Observational

SPINCOMS Biomarker Study

NCT04496830
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin

NCT04717726
View directory record Official record
Conditions
Obesity
Interventions
Milk Thistle (MT), Lactobacillus Gasseri (LAC), Exercise (EX), Control (CON)
Dietary Supplement · Behavioral
Lead sponsor
Kyle Flack
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Phase 1 Interventional

Pain Catastrophizing as a Cause for Systemic Inflammation

NCT00823147
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Pain Catastrophizing Induction
Behavioral
Lead sponsor
Beth Darnall, PhD
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 6, 2026, 7:33 AM EDT
Terminated Phase 1 Interventional

Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease

NCT01894594
View directory record Official record
Conditions
Sickle Cell Anemia, Chronic Kidney Disease, Metabolic Acidosis
Interventions
Sodium Bicarbonate
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 6, 2026, 7:33 AM EDT
Completed No phase listed Observational Results available

Treatment Outcomes for Ankle Arthritis

NCT00391365
View directory record Official record
Conditions
Osteoarthritis
Interventions
Gait analysis
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Phase 1 Interventional Results available

Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia

NCT00718159
View directory record Official record
Conditions
Acute Myeloid Leukemia, Essential Thrombocythemia
Interventions
LY573636-sodium
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 6, 2026, 7:33 AM EDT
Active, not recruiting Not applicable Interventional

Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer

NCT02494869
View directory record Official record
Conditions
High Risk for Developing Breast Cancer
Interventions
Nonlinear Aerobic Training, Height, Weight, BMI measure, Blood draw, Cardiopulmonary exercise test
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia

NCT00495079
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Marqibo® (vincristine sulfate liposomes injection)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Not applicable Interventional

Aortic Valve and Root Measurements Under Real-Time 3-Dimensional Visualization During Angiography

NCT02073617
View directory record Official record
Conditions
Coronary Artery Disease, Aortic Stenosis
Interventions
Real-time 3-dimensional DynaCT
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 6, 2026, 7:33 AM EDT
Recruiting No phase listed Observational

Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 16 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 6, 2026, 7:33 AM EDT
Active, not recruiting Not applicable Interventional

Telehealth Weight Loss Program for Breast Cancer Survivors

NCT04855552
View directory record Official record
Conditions
Cancer Survivors, Cancer of Breast, Body Weight, Overweight and Obesity
Interventions
Behavioral Weight-loss Program Via Telehealth, Behavioral Weight-Loss Program Via Telehealth - Weight Measures, Validated Surveys of Patient-Reported Outcomes
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Not applicable Interventional

Aerobic and Strengthening Exercise for Acute Leukemia

NCT00766311
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Gross Motor Function, Knee extension strength, Hand grip strength, Flexibility, Ankle range of motion, Aerobic capacity, Body composition and vital signs
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 10 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Portland, Oregon • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2012 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance

NCT04831047
View directory record Official record
Conditions
Ptosis, Eyelid, Conjunctiva Inflamed, Eye Manifestations
Interventions
Oxymetazoline hydrochloride 0.1% ophthalmic solution, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 6, 2026, 7:33 AM EDT
Completed Phase 4 Interventional

Exercise Versus DDAVP in Patients With Mild Hemophilia A

NCT03379974
View directory record Official record
Conditions
Hemophilia A
Interventions
DDAVP Inhalant Product, Exercise Intervention
Drug · Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
13 Years to 21 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Indianapolis, Indiana • Akron, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 6, 2026, 7:33 AM EDT